What Stiba Treats: Main Uses and Benefits

Stiba is commonly used across domains where additional symptomatic support is needed, primarily for conditions presenting with systemic or localized discomfort.

Managing Allergic Symptoms and Discomfort

The medication is commonly used for managing symptoms of Allergic Rhinitis, including episodic or fluctuating manifestations of Seasonal Hay Fever and symptoms related to Perennial (year-round) allergies. It is commonly used for skin conditions characterized by periods of heightened symptoms, specifically Chronic Urticaria (hives). This means it is relevant for managing symptom clusters that become more disruptive during flare-ups, such as sneezing, runny nose, nasal obstruction, and symptoms related to inflammatory or irritative states like skin itching (pruritus).

Quick Fact: Relief for Pruritus The medication is considered relevant for easing symptoms related to inflammatory or irritative states, and helps to address symptoms that create noticeable physiological strain like skin itching associated with chronic hives.

It supports the patient during difficult episodes by easing distress and helps with easing the overall symptom burden during periods of heightened symptoms. The therapeutic benefit supports patients during episodes of heightened discomfort by offering symptomatic relief.

Regulatory References

1. Summary of Product Characteristics (Swedish MPA)

Who Can and Cannot Use Stiba?

The population eligibility for Stiba (Ebastine) is defined by official regulatory documents, detailing who is allowed to use the medicine and under what conditions.

Contraindications (Must Not Use)

• Hypersensitivity: The medicine is strictly contraindicated in patients with a known allergy or hypersensitivity to the active substance (Ebastine) or any of the excipients.
• Metabolic Disorders: Use is contraindicated in patients with rare hereditary problems such as total lactase deficiency, galactose intolerance, or glucose-galactose malabsorption.

Population and Condition-Based Restrictions

• Age: Use of the tablet formulation is established for adults and adolescents 12 years of age and above. It is not recommended or not established in children under 12 years.
• Hepatic Impairment: Patients with severe hepatic impairment must not exceed a daily dose of 10 mg. No dose adjustment is necessary for mild to moderate hepatic impairment, or for any degree of renal impairment.
• Reproductive Status: Use is not recommended during breastfeeding and is preferable to avoid during pregnancy due to limited clinical data.
• Cardiovascular Conditions: Caution must be exercised in patients with a known prolongation of the QTc interval on the ECG or those with hypokalaemia, as defined in the official warnings.

Interactions with other medicines and products

The official regulatory profile for Stiba (Ebastine) identifies specific interactions related to drug metabolism and potential cardiac effects. Co-administration with certain medicinal products can significantly alter the systemic levels of Stiba and its active metabolite, Carebastine, in the body.

Substances Affecting Clearance (Pharmacokinetic Interactions)

Ebastine is subject to metabolic interaction by substances that affect the CYP enzyme system. Co-administration with potent inhibitors of the CYP3A4 enzyme, such as ketoconazole or erythromycin, increases the systemic plasma concentrations of Ebastine and Carebastine. Conversely, potent CYP inducers, such as rifampicin, reduce the drug's plasma concentration, which can lead to a reduced overall antihistaminic effect. Caution is also advised regarding concomitant use with inhibitors of the CYP2J2 and CYP4F12 enzyme systems.

Pharmacodynamic and Dietary Interactions

A documented risk exists when Stiba is co-administered with other medicinal products known to prolong the QTc interval, due to the potential for an additive pharmacodynamic effect. No synergistic sedative effects have been documented in regulatory studies when Stiba is taken with alcohol or classical CNS depressants. Taking Stiba with food has a pharmacokinetic effect, increasing the exposure of the active metabolite, Carebastine, by up to two-fold.

Population-Specific Considerations

Regulatory information notes altered drug clearance kinetics in specific patient populations. Due to the prolonged half-life of Carebastine, particular attention is required when Stiba is used in individuals with severe hepatic impairment.

Selective Peripheral H1 Receptor Blockade

The active component, Carebastine, specifically targets and blocks the Histamine H1 Receptor ( H1 R) predominantly in the periphery. By acting as an inverse agonist, it prevents the inflammatory mediator, histamine, from initiating its signaling cascade, contributing to the attenuation of H1 R-driven cellular activity. The active molecule's limited ability to cross the blood-brain barrier restricts its mechanism of action predominantly to the periphery.

Modulation of Vascular and Smooth Muscle Response

This molecular interference with histamine signaling results in altered physiological processes within the microvascular system. Blocking the H1 R limits the histamine-induced increase in vascular permeability and contraction of certain smooth muscles. This mechanism influences fluid exchange in tissues and reduces the intensity of physical responses triggered by histamine release.

Mechanism of Prodrug Activation

The parent molecule, Ebastine, functions as a prodrug, which is rapidly metabolized into the principal active molecule, Carebastine. This conversion is essential for the duration of the drug’s action, as Carebastine provides sustained H1 R blockade, which prolongs the interference with histamine signaling within the targeted pathways.

The administration of Stiba (Ebastine) follows a standardized oral, once-daily protocol. The medicine is available as film-coated tablets, orodispersible tablets (ODT), and an oral solution for different populations.

Official Administration Guidelines

Instruction	Detail (Strictly Label-Based)
Route of administration:	Oral (by mouth).
Dosing schedule:	The standard dose for adults and adolescents (12 years) is 10 mg once daily. The dose may be increased to a maximum of 20 mg once daily for severe symptoms.
Timing in relation to meals:	The medicine may be administered independently of meals (with or without food).
Preparation requirements:	Film-coated tablets must be swallowed unchewed with liquid. The ODT formulation is designed to dissolve directly on the tongue, requiring no water for ingestion.
Age-group administration rules:	The tablet forms (10 mg and 20 mg) are for patients 12 years of age and older. Dosing for younger children is typically managed with the oral solution/syrup form.
Special procedural conditions:	The daily dose must not exceed 10 mg in patients with severe hepatic impairment. No dose adjustment is specified for renal impairment.
Course duration:	Treatment is typically continued until symptoms are relieved; clinical data supports treatment for allergic rhinitis for up to one year.

These official instructions define the standardized use: the specific oral route, the required preparation method for each formulation, and the once-daily frequency. The constraints on dosing reflect the limits defined for populations with severe hepatic impairment, guiding the use protocol.

Research Evidence: Overview of Studies for Stiba

---

**

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)**

The research base that has studied Stiba for the study of symptoms associated with Allergic Rhinitis, including Seasonal Hay Fever and Perennial (year-round) allergies, relies primarily on Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These short-term clinical trials have been studied for up to a few weeks. The studies typically involved Adults and Adolescents (age 12 and older) and were used in research contexts involving fluctuating or unstable symptoms.

Research examined how symptoms evolved in the observed populations by tracking patient-reported measures like the Total Symptom Score (TSS). Studies also explored outcomes related to physical discomfort, such as nasal itching and sneezing, and examined the impact on daily functioning. Findings describe patterns observed in the studies related to how these symptoms evolved during the short-term study period.

---

**

Evidence for Use in Chronic Urticaria (Hives)**

Stiba was evaluated in studies focused on research exploring the management of symptoms for Chronic Urticaria (hives). This research mainly consisted of Randomized Controlled Trials (RCTs) that typically ran for intermediate periods. The study populations focused on adult patients with this skin condition, which is marked by functional limitations.

These studies monitored outcomes linked to inflammatory or irritative states of the skin. Researchers primarily used a measurement called the Urticaria Activity Score (UAS7), which combines the severity of pruritus (itching) and the size/number of wheals (hives). Research highlights changes measured during the study period for both the itching and the physical appearance of the hives.

---

**

Long-Term Studies and Durability of Symptom Management**

Research exploring short-term symptom changes in the core RCTs for allergic rhinitis was typically limited to follow-up durations of one to four weeks. While some chronic urticaria studies have extended to twelve weeks, long-term effects are not fully established and data for long-term outcomes remain insufficient.

**

Evidence in Specific Study Populations**

The main research that examined Stiba focused on outcomes in Adults and Adolescents (aged 12 years and above). Therefore, the results apply only to the populations studied. The available research provides limited insight into the symptom patterns observed for older adults (age ge 65 years) due to modest sample sizes.

Key Studies & References SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebastine Viatris 10 mg Orodispersible Tablets

Common questions about Stiba (FAQ)

---

Q: What kind of drug is Stiba?

Stiba is an anti-inflammatory drug that works to relieve symptoms of rheumatoid arthritis and psoriatic arthritis. According to the official product information, it belongs to a class of medicines called selective Janus Kinase (JAK) inhibitors. This means it works by blocking the activity of certain enzymes in the body to help reduce inflammation.

---

Q: How long will it take for Stiba to start working?

Clinical trial data suggests that some patients may begin to see an improvement in symptoms as early as a few weeks after starting treatment with Stiba. However, the full benefit of the medicine may take longer to achieve. The specific timeline can vary widely between individuals.

---

Q: Is Stiba a biologic drug?

No, Stiba is not a biologic drug. Biologics are medicines made from living cells. Official product information classifies Stiba as a targeted synthetic disease-modifying antirheumatic drug (tsDMARD), which is made using chemical synthesis. It is a small molecule drug that works inside the cells to block specific pathways.

---

Q: How is Stiba typically taken?

Stiba is available as film-coated tablets that are taken orally. Official labeling indicates it is taken as a tablet, and the dosing schedule is typically once daily. The tablet can generally be taken with or without food.

---

Q: What should I do if I miss a dose of Stiba?

Official product labeling recommends that if a dose is missed, it should be taken as soon as it's remembered, unless it is close to the time for the next dose. If it is almost time for the next dose, the missed dose should be skipped entirely. The label also advises against taking two doses at once to compensate for a missed dose.

---

Q: Does Stiba need to be refrigerated?

No, Stiba does not need to be refrigerated. The official product information states that Stiba tablets should be stored at room temperature (below 30 C or 86 F). It should be kept in the original container to protect it from moisture.

How to Store and Dispose of Stiba?

Storing Stiba (Ebastine) according to its official regulatory label is necessary to ensure the medicine's stability and efficacy.

---

Mandatory Storage Conditions

Requirement	Official Instruction
Temperature	Store below 30 C.
Protection	Store in the original package to protect from light and moisture.
Child Safety	Keep this medicine out of the sight and reach of children.

---

Disposal Requirements

Stiba must not be thrown away with household waste or flushed down the toilet (wastewater). Disposal of expired or unused medicine must strictly follow the guidance of a pharmacist or the local/national regulations for pharmaceutical waste, which helps protect the environment. Do not use the medicine after the expiry date printed on the packaging.